These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 18808741

  • 1. The trials and errors in MS therapy.
    Kleinschnitz C, Meuth SG, Wiendl H.
    Int MS J; 2008 Sep; 15(3):79-90. PubMed ID: 18808741
    [Abstract] [Full Text] [Related]

  • 2. [Multiple sclerosis: between wish and reality].
    Kümpfel T, Hohlfeld R.
    MMW Fortschr Med; 2005 May 17; 147 Spec No 2():83-5. PubMed ID: 15968879
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
    Ulzheimer JC, Meuth SG, Bittner S, Kleinschnitz C, Kieseier BC, Wiendl H.
    BioDrugs; 2010 Aug 01; 24(4):249-74. PubMed ID: 20623991
    [Abstract] [Full Text] [Related]

  • 4. Novel therapeutic options for multiple sclerosis.
    Curtin F, Hartung HP.
    Expert Rev Clin Pharmacol; 2014 Jan 01; 7(1):91-104. PubMed ID: 24325127
    [Abstract] [Full Text] [Related]

  • 5. Spotlight on anti-CD25: daclizumab in MS.
    Schippling DS, Martin R.
    Int MS J; 2008 Sep 01; 15(3):94-8. PubMed ID: 18808743
    [Abstract] [Full Text] [Related]

  • 6. Ocrelizumab: a B-cell depleting therapy for multiple sclerosis.
    Jakimovski D, Weinstock-Guttman B, Ramanathan M, Kolb C, Hojnacki D, Minagar A, Zivadinov R.
    Expert Opin Biol Ther; 2017 Sep 01; 17(9):1163-1172. PubMed ID: 28658986
    [Abstract] [Full Text] [Related]

  • 7. A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.
    Holmén C, Piehl F, Hillert J, Fogdell-Hahn A, Lundkvist M, Karlberg E, Nilsson P, Dahle C, Feltelius N, Svenningsson A, Lycke J, Olsson T.
    Mult Scler; 2011 Jun 01; 17(6):708-19. PubMed ID: 21228027
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis.
    Vollmer TL, Wynn DR, Alam MS, Valdes J.
    Mult Scler; 2011 Feb 01; 17(2):181-91. PubMed ID: 21135022
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H, Hohlfeld R.
    BioDrugs; 2002 Feb 01; 16(3):183-200. PubMed ID: 12102646
    [Abstract] [Full Text] [Related]

  • 14. Drugs in development for relapsing multiple sclerosis.
    Ali R, Nicholas RS, Muraro PA.
    Drugs; 2013 May 01; 73(7):625-50. PubMed ID: 23609782
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Therapeutic indications targeting etiology. (With the exception of primary progressive forms)].
    Brassat D.
    Rev Neurol (Paris); 2001 Sep 01; 157(8-9 Pt 2):1014-28. PubMed ID: 11787332
    [Abstract] [Full Text] [Related]

  • 17. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.
    Neurology; 2007 Oct 09; 69(15):1498-507. PubMed ID: 17699802
    [Abstract] [Full Text] [Related]

  • 18. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 09; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 19. Emerging injectable therapies for multiple sclerosis.
    Oh J, Calabresi PA.
    Lancet Neurol; 2013 Nov 09; 12(11):1115-26. PubMed ID: 24090587
    [Abstract] [Full Text] [Related]

  • 20. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis.
    Gajofatto A, Turatti M.
    Expert Opin Investig Drugs; 2018 Mar 09; 27(3):273-286. PubMed ID: 29455558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.